StockData
Cooper Companies, Inc. logo

Cooper Companies, Inc. (COO) company profile

COONasdaqOphthalmic GoodsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 16/3040% below fair value
$60.72−1.16 (-1.87%)

Close on Nov 17, 2026Market cap $11.55BP/E 20.7Yield –

About Cooper Companies

Ophthalmic Goods, SIC 3851

The Cooper Companies, Inc. is a global medical device company operating primarily through two business segments: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets a broad range of contact lenses, including spherical, toric, multifocal, and silicone hydrogel products. CooperSurgical focuses on healthcare solutions centered on women's health, fertility, and diagnostics, offering medical devices, surgical equipment, and specialized fertility technologies. The company serves healthcare professionals, fertility clinics, medical practices, hospitals, and consumers across vision care and surgical markets worldwide.

The company maintains extensive international operations spanning the United States, Europe, and other global regions. It conducts research, development, manufacturing, and distribution activities through facilities across multiple countries to support its commercial presence. The principal executive offices and corporate headquarters are located in San Ramon, California.

Summary of the business section of Cooper Companies's latest annual report, written by StockData.

Company profile

Company

Legal name
Cooper Companies, Inc.
Founded
1958
Headquarters
San Ramon, CA
Address
6101 Bollinger Canyon Road, Suite 500 94583
Phone
(925) 460-3600
Employees
500, Oct 31, 2025
Industry
Ophthalmic Goods
Incorporated in
Delaware
Fiscal year ends
October 31
Auditor
KPMG LLP, San Francisco, CA

Stock & identifiers

Ticker
COO
Exchange
Nasdaq
IPO date
Jan 21, 1983
Shares outstanding
190M, Sep 3, 2026
Public float
$16.20B, Apr 30, 2025
Filer category
Large accelerated filer
Stock splits
4-for-1, Feb 20, 2024; 2-for-1, Nov 25, 2002; 1-for-3 reverse, Sep 22, 1995
SEC CIK
711404
CUSIP
216648501
ISIN
US2166485019
FIGI
BBG000BG3445
Share class FIGI
BBG001S5Q1H6
LEI
QJKMVPIGLH7530PCUE20
EIN
94-2657368

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Albert G. White IIIPresident & CEO, Director254,491
Brian G. AndrewsEVP, CFO & Treasurer30,728
Gerard H. Warner IIIPresident, CooperVision, Inc.20,971
Holly R. SheffieldPresident, CSI48,516
Daniel G. McBrideEVP & Chief Operating Officer165,967
Agostino RicupatiSVP & CAO8,020
Nicholas KhadderVP, General Counsel & Corp Sec3,790
Lawrence Erik KurziusDirector31,099
Paul A. KeelDirector4,701
Walter M. Rosebrough JrDirector20,832
Barbara CarboneDirector3,050
Robert S. WeissDirector550,459
Colleen JayDirector39,907
Maria RivasDirector14,463
Teresa S. MaddenDirector15,679
Cynthia L. LuccheseDirector12,767
William A. KozyDirector31,149

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$16.05M$1.77M$4.12M$67$104
FY2024$15.43M$39.83M$3.77M$100$98
FY2023$13.49M$22.31M$3.46M$75$75
FY2022$11.74M-$9.23M$3.12M$66$77
FY2021$10.99M$36.21M$2.77M$100$100

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Albert G. White III
President & Chief Executive Officer
$1.17M$6.64M$6.64M$1.53M$68.45K$16.05M+4%
Brian G. Andrews
Executive Vice President, Chief Financial Officer & Treasurer
$734.62K$1.50M$1.50M$555.33K$47.74K$4.34M+16%
Daniel G. McBride
Executive Vice President, Chief Operating Officer, General Counsel & Secretary
$792.31K$3.30M–$639.24K$91.53K$4.82M+1%
Holly R. Sheffield
President, CooperSurgical, Inc.
$646.15K$2.50M–$435.54K$75.01K$3.66M+6%
Gerard H. Warner III
President, CooperVision, Inc.
$634.62K$2.50M–$434.50K$75.73K$3.64M+16%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“The Company employs approximately 500 people in research and development.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?